Abstract: A foot stretcher assembly for stretching a foot includes a foot stretcher and a handle removably secured with the foot stretcher. The foot stretcher includes a sole that is flexible in response to receiving a foot. The foot stretcher assembly can also include a securing feature to maintain the foot relative to the foot stretcher.

Abstract: A device for use by a female for sexual stimulation comprising an inner arm dimensioned for insertion into a vagina, to contact the wall of the vagina at or near the G-spot, an outer arm dimensioned to contact the clitoris, and a resilient U-shaped member connecting the inner and outer arms.

Abstract: A device for mutual sexual stimulation of partners is provided. The device includes a central area forming a base for at least three arms that extend therefrom in a common plane, the three arms comprising a pair of outer arms and an inner arm that is disposed in the common plane between the outer arms, where each of the outer arms includes at least one pressure sensor and at least one vibration motor. The device also includes a controller operatively coupled with the at least one pressure sensor and the at least one vibration motor, and configured to detect a pressure applied to a first outer arm of the pair of outer arms and activate the vibration motor in a second outer arm of the pair of outer arms in response to the detected pressure.

Abstract: A massage apparatus is provided. The massage apparatus includes a housing, an active assembly and a flexible component. The active assembly, which is fixed on one side of the housing approximately along an axis, includes an adjusting motor, a plurality of adjustable elements and a plurality of supporting elements. The flexible component clads the active assembly. The adjustable elements surrounding the axis are located outside the adjusting motor. The supporting elements surrounding the axis are located outside the adjustable elements and correspondingly coupled to the adjustable elements. The adjusting motor drives the adjustable elements to move toward directions different form the axis so that the support elements adjust the flexible component toward the directions different form the axis.

Abstract: The present disclosure relates to a system and process for manufacturing patient personalized pharmaceutical compositions using superimposed revolution and rotation movements for dispersing, milling, melting, and/or de-aerating, where these superimposed revolution and rotation movements can be carried out in a single device in a pharmacy setting.

Abstract: A cooler for maintaining an internal temperature while simultaneously protecting contents stored therein from UV light may include a container body with an interior region, the interior region sized to accommodate items to be kept within a desired temperature range; a lid hingeably attached to the container body; an angled lip extending from an outer edge of the container body; and at least one holster built into the angled lip, wherein the at least one holster is sized to accommodate a vaccine gun. The cooler may also include an alerting temperature gauge configured to alert a user when the temperature in the interior region falls outside of the desired temperature range.

Abstract: The present invention relates to providing a dental curable composition that, when cured, has high metal ion release ability and highly durable physical properties. The dental curable composition of the present invention includes: a sugar compound having an —XM group, where —X is an acid anion group and M is a metal cation; and a curable component.

Abstract: A composition of matter includes one or more functionalized vinylbenzyl components of the formula wherein n is an integer equal to or greater than 1 covalently connected to one or more R functional components; the one or more R functional groups selected from a group including one or more hydroxyl methyl (—CHOH—) moieties and/or derivatives thereof, one or more ethoxy (—CH2—CH2—O—) moieties and/or derivatives thereof, and one or more benzene derivatives; and ether links that connect the functionalized vinylbenzyl components and the R functional components.

Abstract: Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.

Abstract: A method of reducing hair loss (alopecia) in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves administering brimonidine or a pharmaceutically acceptable salt thereof to the site of the hair follicles.

Abstract: The present invention provides an intermediate composition enabling to prepare easily and steadily an ?-gel-containing O/W emulsion cosmetic that has a very small viscosity change over time and is excellent in emulsion stability, without using a cooling device that has a heavy burden on cost and the environment, and a production method thereof. An ?-gel intermediate composition consisting of (A) 20 to 80 mass % of a mixture containing one or more higher alcohols having 16 or more carbon atoms and an anionic surfactant in the mole ratio of 3:2 to 5:1, and (B) 20 to 80 mass % of a mixture containing one or more water-soluble solvents having the IOB value of 1.5 to 3.5 and water in the mass ratio of 5:5 to 8:2, and wherein the composition is a liquid consisting of a bicontinuous microemulsion phase or a lamellar liquid crystal-dispersed bicontinuous microemulsion phase at 65 to 85° C. and a solid at room temperature.

Abstract: An oral care composition comprising 20% to 75% of water by weight of the composition; 25% to 60% of a calcium-containing abrasive by weight of the composition; 0.001% to 5% of a flavorant by weight of the composition; and a rheology profile characterized by at least one of the following parameters: 10*K (Pa·s) value from 100 to 3,000; (?10000*)n (rate index) value from ?5000 to ?1300; 10*Yield Stress value from 100 to 3,500; Average G? value from 100 to 2000; or Average G? value 100 to 1000.

Abstract: An oil base skin care composition including squalane and a method for treating skin are disclosed. The method includes the step of individually displaying a plurality of visual skin guides to a consumer. Each of the visual skin guides includes a plurality of visual representations of a categorical skin condition. Each of the visual representations correspond to a severity score for the categorical skin condition on the visual skin guide. The method further includes correlating the severity score for each of the categorical skin conditions for each of the visual skin guides to the consumer's current skin condition. At least two target skin conditions from the plurality of categorical skin conditions are determined in response to the severity scores for each of the categorical skin conditions. At least one booster containing at least one active ingredient is correlated for treating each target skin condition.

Abstract: A first agent for oxidation hair dye contains a carbonate, the first agent including (A) at least one selected from resorcin and its derivatives, and salts thereof, an upper limit of a compounding amount of the component (A) being 0.2% by mass or less, (B) at least one coupler selected from m-aminophenol, 5-amino-o-cresol, and ?-naphthol, and (C) 0.01 to 0.45% by mass of at least one dye intermediate selected from p-phenylenediamine, toluene-2,5-diamine, p-aminophenol, N,N-bis(2-hydroxyethyl)-p-phenylenediamine, and derivatives thereof, and salts thereof, a mass ratio of a content of the component (B) to a content of the component (A) being 0.5 to 10.

Abstract: Desensitizing oral care composition useful for treating dentinal hypersensitivity, comprising potassium oxalate and methods of use thereof. Delivery systems including a strip of material and such oral care compositions for the treatment of dentinal hypersensitivity and methods of use thereof.

Abstract: The embodiments herein discloses a composition and method for the synthesis of an effervescence producing tablet for reducing and eliminating a mouth odor and oral staining caused by ingested beverages and food. The method comprises mixing excipients, disintegrating agents, flavor and sweetener in a V-blender. The lubricant is added V-blender to obtain a mixture. The mixture is compressed on tablet press equipment with a round tooling. The tablets are packaged in a foil pouch. The “excipients” in the effervescent tablet composition are malic acid, sorbitol, potassium bi-carbonate, microcrystalline cellulose, sodium chloride, sodium carbonate and magnesium oxide. The malic acid react with potassium bicarbonate or sodium bicarbonate or sodium carbonate to form an effervescence reaction to induce tablet disintegration, provide a pleasant sensation in the mouth, and to clean a wine stain in the mouth.

Abstract: The disclosure relates to systems and compositions comprising the systems for use in chemical treatment of keratinous substrates, such as the hair. The systems and compositions comprising the systems comprise at least one active agent and at least one acid. Methods of treating keratinous substrates with the systems and compositions comprising the systems are also disclosed.

Abstract: The invention is directed to the use of at least one peptide of formula: X—(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, 1 or 2; —m=0 or 1 and if m=0 then n?0-Xaai is: —An hydrophobic amino acid; —A polar amino acid; —or Glycine (Gly, G); When n=2 the two amino acids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic amino acid; —A basic amino acid Glycine (Gly, G) or Serine (Ser, S); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; —At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 or NR1R2, R1 and R2 being independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group; Excluding the peptides where X=H and Y=OH, for a non therapeutical cosmetic pro-pigmenting treatment of skin.

Abstract: A cosmetic agent for the temporary deformation of keratinous fibers and a method for the temporary deformation of keratinous fibers using the cosmetic agent are provided. The cosmetic agent comprises: a) a cosmetic preparation containing a1) at least one copolymer composed at least of the following monomer units: styrene acrylic acid and/or methacrylic acid; a2) at least one copolymer composed at least of the following monomer units: N-tert-butylacrylamide acrylic acid ethyl acrylate, wherein the weight fraction of copolymers a1) and a2) in the total weight of the cosmetic preparationis about 1.0 to about 10% by weight.

Abstract: The present disclosure relates to a cosmetic composition comprising: (a) Sulfopolyester; and (b) Styrene/Acrylates/Ammonium Methacrylate copolymer; wherein the combination of the sulfopolyeseter and Styrene/Acrylates/Ammonium Methacrylate copolymer improves the water resistance of the cosmetic composition and reduces the stickiness of the cosmetic composition.

Abstract: A skin cleansing composition comprising the following components (A), (B), (C), (D), (E), (F), and (G): (A) from 0.5 to 20% by mass of an oil agent having a viscosity at 30° C. of more than 30 mPa·s, (B) from 0.5 to 20% by mass of an oil agent having a viscosity at 30° C. of 30 mPa·s or less, (C) from 1 to 15% by mass of a nonionic surfactant having an HLB of 10 or more and having a residue obtained by removing a hydrogen atom from at least one hydroxyl group in sugar, reducing sugar, or polyglycerin as a hydrophilic group, (D) from 1 to 15% by mass of a nonionic surfactant having an HLB of 8 or less, (E) from 10 to 60% by mass of a polyhydric alcohol, (F) from 10 to 50% by mass of water, and (G) from 4 to 45% by mass of a nonionic surfactant having an HLB of 10 or more and having a polyoxyethylene chain as a hydrophilic group, wherein the mass ratio of the component (A) to the components (B), (A)/(B), is from 0.

Abstract: The present invention relates to the cosmetic use, as an agent for treating greasy skin and/or preventing greasy or greasy-prone skin and/or the associated aesthetic skin defects, of an essential oil of Origanum majorana and/or of origanum hybrids. The invention also relates to a cosmetic composition comprising same, to a non-therapeutic cosmetic care and/or cleansing treatment process for greasy skin, and also to said essential oil as a dermatological agent.

Abstract: Disclosed is a method for moisturizing skin. The method can include topically applying to skin in need thereof a composition comprising 0.01 to 3% by weight of lactobacillus ferment, 0.001 to 1% by weight of Ferula foetida root extract, 0.001 to 1% by weight of Helianthus annuus (sunflower) seed extract, 0.001 to 1% by weight of Terminalia ferdinandiana fruit extract, and 0.1 to 3% by weight of niacinamide, wherein the skin in need thereof is dry skin.

Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.

Abstract: A compounded topical composition may include an antiviral component, a topical base component, and a local anesthetic component. The antiviral component may include fine powder obtained by grinding oral tablets of one or more antiviral actives. The topical component may include the local anesthetic component. The local anesthetic component may be present in an amount between about 2% and about 8% by weight of the compounded topical composition and the antiviral component may be present in an amount between 4% and 12% by weight of the compounded topical composition. The antiviral component may include acyclovir, valaciclovir, penciclovir, famciclovir, or combinations thereof, and the topical base component may be a lidocaine topical, a lidocaine and prilocaine topical, or both.

Abstract: The invention relates to the use of quaternary ammonium compounds for preventing precipitations of fluoroquinolones from their solutions and to stable, tolerated pharmaceuticals which are particularly suitable for parenteral use and which contain, in dissolved form, a fluoroquinolone and a quaternary ammonium compound.

Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: A vehicle braking arrangement includes an axle member, a brake torque plate having a first portion fixedly coupled to the axle member, and a second portion laterally offset from the first portion, and a brake caliper member coupled to the second portion of the brake torque plate such that the first portion of the brake torque plate is spaced from the brake caliper.

Abstract: A solid dispersion for achieving improved solubility and absorbability of a pharmaceutically active ingredient, which contains (1) an amorphous pharmaceutically active ingredient, (2) one or more substances selected from among methyl cellulose and organic acids and (3) an enteric base material. In cases where methyl cellulose is contained therein, the solid dispersion does not contain any water-soluble polymer other than methyl cellulose.

Abstract: The present invention provides a method for producing a pharmaceutical composition which is a tablet and which contains tofogliflozin as an active ingredient. The method comprises mixing an additive and tofogliflozin to prepare a powder mixture and obtaining a tablet from the powder mixture by direct compression. The additive comprises at least one filler.

Abstract: Novel thyroid hormone oral dosage forms and methods of making and using the thyroid hormone oral dosage forms are disclosed.

Abstract: Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.

Abstract: An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.

Abstract: The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.

Abstract: The present invention relates to a process for manufacturing pullulan hard capsules having improved film properties. More particularly, the present invention relates to a process for manufacturing pullulan hard capsules having improved film properties by solving the problems, such as, sticky among pullulan hard capsules, storage stability and/or brittleness.

Abstract: Delivery of a drug is controlled to impart a delay before release after administration by formulating the drug with a disruption agent to provide a core, and coating the core with a regulatory membrane comprising a water-soluble gel-forming polymer and a water-insoluble film-forming polymer.

Abstract: An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.

Abstract: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

Abstract: Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided.

Abstract: Methods of making safe extracts of Curcuma longa L. are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single extraction than the state-of-the-art processes. For example, liquid dosage forms can be produced directly from the extraction process without requiring removal of the extraction solvent, reducing complexity and cost of processing over the state-of-the-art. Methods of making microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts.

Abstract: The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.

Abstract: A method for treating a fibrous mass, which comprises a Morton's neuroma or a plantar firbroma. The method comprises identifying a location of the fibrous mass, determining a first size of the fibrous mass, non-surgically delivering electromagnetic energy to the fibrous mass, and determining a second size of the fibrous mass.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

Abstract: The present invention relates to the compositions comprising 15-HEPE and methods of treatment relating to same.

Abstract: The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor.

Abstract: The invention provides compounds of formula I: and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers, Alzheimer's disease, and conditions associated with demyelination.

Abstract: Compositions, systems, and methods that can be used with a pressurized metered dose inhaler are disclosed. A pharmaceutical composition for use in a pressurized metered dose inhaler can comprise a cannabinoid composition, a co-solvent, a terpene composition, and a propellant. A pharmaceutical composition may be soluble. A system can comprise a plurality of cannabinoid compositions and/or a plurality of terpene compositions available in various combinations. One of a plurality of cannabinoid compositions and terpene composition combinations may be user-selectable in response to various factors such as a desired therapeutic benefit, sedative effect, flavor profile, or a combination of the foregoing. A method of formulating a soluble pMDI pharmaceutical composition comprising a cannabinoid composition, a co-solvent, a terpene composition, and a propellant is disclosed.

Abstract: Provided herein are compositions and methods for inhibiting cancer cell motility and/or metastasis. In particular embodiments, KBU2046 (or an analog thereof) and one or more additional therapies (e.g., cancer therapies (e.g., hormone therapies and chemotherapies) are provided to inhibit cancer cell motility, inhibit metastasis, and/or treat cancer (e.g., prostate cancer, lung cancer, breast cancer, colon cancer, etc.).